Warszawa Centrum - Warszawa, Poland

FutureMeds

Sjogren's Syndrome

argenx

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

FutureMeds | Warszawa Centrum - Warszawa, Poland

Site insights

Work at this site?

Active trials

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome (Unity)

Trial sponsors